The recently formed Lung Ambition Alliance seeks to double the five-year survival rate for lung cancer—up to 40%, by 2025.
Amarinthia Curtis has a community doctor's perspective on the scientific questions the Tomosynthesis Mammographic Imaging Screening Trial seeks to address.
Nearly three years after its introduction, the CMS's Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.
The Cancer Letter won four 2019 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:
The FDA Oncology Center of Excellence announced a pilot program to help physicians get access to unapproved therapies for patients with cancer.
Project ECHO, a service that provides physicians in rural areas with access to multidisciplinary expertise, will soon announce partnerships with four cancer centers—Dana-Farber Cancer Institute, Mayo Clinic Cancer Center, University of New Mexico Comprehensive Cancer Center, and Yale Cancer Center.
Over the past decade there has been much consternation about overdiagnosis, the detection of cancers that would not have been diagnosed without screening.
Overdiagnosis is defined as the diagnosis of an asymptomatic cancer that would not have become clinically evident during the person's lifetime in the absence of screening or similar activities, such as diagnostic imaging tests that reveal “incidentalomas.”
Community oncology needs to adapt to the era of precision oncology and Big Data, said Lee Schwartzberg, executive director of Memphis-based West Cancer Center, who was recently named chief medical officer of OneOncology, a partnership between three oncology practices located in Tennessee and New York.
Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.”
